UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 30

Sortiert nach

PSA doubling time predicts the outcome after active surveillance in screening‐detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section

International journal of cancer, 2007-01, Vol.120 (1), p.170-174

2007

Volltextzugriff (PDF)

Prostate cancer grading, time to go back to the future

BJU international, 2021-02, Vol.127 (2), p.165-168

2021

Volltextzugriff (PDF)

Results of a randomized, population‐based study of biennial screening using serum prostate‐specific antigen measurement to detect prostate carcinoma

Cancer, 2004-04, Vol.100 (7), p.1397-1405

2004

Volltextzugriff (PDF)

Prostate Cancer Diffusion‐Weighted Magnetic Resonance Imaging: Does the Choice of Diffusion‐Weighting Level Matter?

Journal of magnetic resonance imaging, 2022-03, Vol.55 (3), p.842-853

2022

Volltextzugriff (PDF)

Surgeon heterogeneity significantly affects functional and oncological outcomes after radical prostatectomy in the Swedish LAPPRO trial

BJU international, 2021-03, Vol.127 (3), p.361-368

2021

Volltextzugriff (PDF)

Oncological and functional outcomes 1 year after radical prostatectomy for very‐low‐risk prostate cancer: results from the prospective LAPPRO trial

BJU international, 2016-08, Vol.118 (2), p.205-212

2016

Volltextzugriff (PDF)

The Movember Foundation's GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date

BJU international, 2018-05, Vol.121 (5), p.737-744

2018

Volltextzugriff (PDF)

Four-hundredfold overestimation of biopsy mortality

BJU international, 2013-03, Vol.111 (3), p.E16-E17

2013

Volltextzugriff (PDF)

Population‐based, nationwide registration of prostatectomies in Sweden

Journal of surgical oncology, 2019-09, Vol.120 (4), p.803-812

2019

Volltextzugriff (PDF)

Social constraints and psychological well‐being after prostate cancer: A follow‐up at 12 and 24 months after surgery

Psycho-oncology (Chichester, England), 2018-02, Vol.27 (2), p.668-675

2018

Volltextzugriff (PDF)

Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis

Cancer, 2016-11, Vol.122 (21), p.3386-3393

2016

Volltextzugriff (PDF)

Impact of Recent Screening on Predicting the Outcome of Prostate Cancer Biopsy in Men With Elevated Prostate-Specific Antigen: Data From the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden

Cancer, 2010-06, Vol.116 (11), p.2612-2620

2010

Volltextzugriff (PDF)

The absence of voiding symptoms in men with a prostate‐specific antigen (PSA) concentration of ≥3.0 ng/mL is an independent risk factor for prostate cancer: results from the Gothenburg Randomized Screening Trial

BJU international, 2012-09, Vol.110 (5), p.638-643

2012

Volltextzugriff (PDF)

Is delayed radical prostatectomy in men with low‐risk screen‐detected prostate cancer associated with a higher risk of unfavorable outcomes?

Cancer, 2010-03, Vol.116 (5), p.1281-1290

2010

Volltextzugriff (PDF)

Correlation between stage shift and differences in mortality in the European Randomised study of Screening for Prostate Cancer (ERSPC)

BJU international, 2016-11, Vol.118 (5), p.677-680

2016

Volltextzugriff (PDF)

The effect of study arm on prostate cancer treatment in the large screening trial ERSPC

International journal of cancer, 2010-05, Vol.126 (10), p.2387-2393

2010

Volltextzugriff (PDF)

Risk of Dying From Prostate Cancer in Men Randomized to Screening: Differences Between Attendees and Nonattendees

Cancer, 2009-12, Vol.115 (24), p.5672-5679

2009

Volltextzugriff (PDF)

Novel approaches to improve prostate cancer diagnosis and management in early‐stage disease

BJU international, 2012-03, Vol.109 (s2), p.1-7

2012

Volltextzugriff (PDF)

Large‐scale randomized prostate cancer screening trials: Program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial

International journal of cancer, 2002-01, Vol.97 (2), p.237-244

2002

Volltextzugriff (PDF)

No excess mortality after prostate biopsy: results from the European Randomized Study of Screening for Prostate Cancer

BJU international, 2011-06, Vol.107 (12), p.1912-1917

2011

Volltextzugriff (PDF)

Lead time associated with screening for prostate cancer

International journal of cancer, 2004-01, Vol.108 (1), p.122-129

2004

Volltextzugriff (PDF)

Can one blood draw replace transrectal ultrasonography‐estimated prostate volume to predict prostate cancer risk?

BJU international, 2013-09, Vol.112 (5), p.602-609

2013

Volltextzugriff (PDF)

Gleason score 7 screen‐detected prostate cancers initially managed expectantly: outcomes in 50 men

BJU international, 2009-06, Vol.103 (11), p.1472-1477

2009

Volltextzugriff (PDF)

Assessment of intra-individual variation in prostate-specific antigen levels in a biennial randomized prostate cancer screening program in Sweden

The Prostate, 2005-11, Vol.65 (3), p.216-221

2005

Volltextzugriff (PDF)

Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam Region)

The Prostate, 1999-06, Vol.39 (4), p.316-322

1999

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Aktive Filter

KollektionWiley Online Library Full Collection 2018

ThemaMale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(30)

Sprache

Englisch
(30)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Bju International
(13)
International Journal Of Cancer
(6)
Cancer
(5)
Int J Cancer
(3)
The Prostate
(3)
Journal Of Magnetic Resonance Imaging
(1)
Journal Of Surgical Oncology
(1)
Prostate
(1)
Psycho-Oncology
(1)
The prostate/the prostate
(1)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

PSA doubling time predicts the outcome after active surveillance in screening‐detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section

Prostate cancer grading, time to go back to the future

Results of a randomized, population‐based study of biennial screening using serum prostate‐specific antigen measurement to detect prostate carcinoma

Prostate Cancer Diffusion‐Weighted Magnetic Resonance Imaging: Does the Choice of Diffusion‐Weighting Level Matter?

Surgeon heterogeneity significantly affects functional and oncological outcomes after radical prostatectomy in the Swedish LAPPRO trial

Oncological and functional outcomes 1 year after radical prostatectomy for very‐low‐risk prostate cancer: results from the prospective LAPPRO trial

The Movember Foundation's GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date

Four-hundredfold overestimation of biopsy mortality

Population‐based, nationwide registration of prostatectomies in Sweden

Social constraints and psychological well‐being after prostate cancer: A follow‐up at 12 and 24 months after surgery

Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis

Impact of Recent Screening on Predicting the Outcome of Prostate Cancer Biopsy in Men With Elevated Prostate-Specific Antigen: Data From the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden

The absence of voiding symptoms in men with a prostate‐specific antigen (PSA) concentration of ≥3.0 ng/mL is an independent risk factor for prostate cancer: results from the Gothenburg Randomized Screening Trial

Is delayed radical prostatectomy in men with low‐risk screen‐detected prostate cancer associated with a higher risk of unfavorable outcomes?

Correlation between stage shift and differences in mortality in the European Randomised study of Screening for Prostate Cancer (ERSPC)

The effect of study arm on prostate cancer treatment in the large screening trial ERSPC

Risk of Dying From Prostate Cancer in Men Randomized to Screening: Differences Between Attendees and Nonattendees

Novel approaches to improve prostate cancer diagnosis and management in early‐stage disease

Large‐scale randomized prostate cancer screening trials: Program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial

No excess mortality after prostate biopsy: results from the European Randomized Study of Screening for Prostate Cancer

Lead time associated with screening for prostate cancer

Can one blood draw replace transrectal ultrasonography‐estimated prostate volume to predict prostate cancer risk?

Gleason score 7 screen‐detected prostate cancers initially managed expectantly: outcomes in 50 men

Assessment of intra-individual variation in prostate-specific antigen levels in a biennial randomized prostate cancer screening program in Sweden

Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam Region)

Aktive Filter

Suchergebnisse filtern